Bose George

Henry Coffey

Fred Small

Brian Morrison

Mark Hammond

- Park Ha Biological Technology Co., Ltd. reported a **45% increase** in total revenue to **$1,239,197** for the six months ended April 30, 2025, compared to $852,928 for the same period in 2024.  **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:2]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:3]**  However, the company recorded a **net loss of $19,835,994** for the period, a significant decline from a net income of $48,900 in the prior year, resulting in an **EPS of ($0.74)**.  **[1986247_0001213900-25-080494_ea025446601ex99-2_parkha.htm:1]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:2]** 
- The substantial net loss was primarily attributed to a **4464% increase** in general and administrative expenses, which surged to **$20,632,549** for the six months ended April 30, 2025, largely driven by **$19,950,000** in share-based compensation expense.  **[1986247_0001213900-25-080494_ea025446601ex99-2_parkha.htm:1]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:2]** **[1986247_0001213900-25-080494_ea025446601ex99-2_parkha.htm:2]** 
- Cash and cash equivalents increased to **$1,351,285** as of April 30, 2025, from $547,498 as of October 31, 2024, primarily due to **$3,833,511** in net cash provided by financing activities, mainly from the issuance of shares.  **[1986247_0001213900-25-080494_ea025446601ex99-2_parkha.htm:0]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:7]** 
- The number of franchisees decreased to **39** as of April 30, 2025, from 43 as of April 30, 2024.  **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:0]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:4]**

Park Ha Biological Technology (PHH)